Memantine Synthesis via Basic Hydrolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing 1-amino-3,5-dimethyladamantane, such as Memantine, require harsh reaction conditions, including high temperatures and long hydrolysis times, leading to increased production costs and unwanted by-products, especially under acidic conditions which are not suitable for forming other pharmaceutically acceptable salts.
Innovation Solution
The hydrolysis of 1-formamido-3,5-dimethyladamantane is conducted under basic conditions in a protic solvent, significantly reducing hydrolysis time to approximately one hour and achieving high yields with mild temperatures, allowing for the direct formation of the hydrochloride salt and other pharmaceutically acceptable salts without the need for additional steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If acid hydrolysis is used to produce 1-amino-3,5-dimethyladamantane, then the hydrochloride salt can be obtained directly, but the hydrolysis time is extended to 24 hours and unwanted by-products are formed
Solution Approach 1:
The patent changes the fundamental parameter of hydrolysis conditions from acidic to basic. By using basic hydrolysis with sodium hydroxide or potassium hydroxide in aprotic solvents like dimethyl carbonate or ethyl methyl carbonate, the hydrolysis time is reduced from 24 hours to approximately 1 hour, while avoiding the formation of unwanted by-products associated with acid hydrolysis.
Solution Approach 2:
The patent introduces an intermediary step where the basic hydrolysis first produces the free base form of 1-amino-3,5-dimethyladamantane, which is then converted to the hydrochloride salt or other pharmaceutically acceptable salts in a separate step. This intermediary approach allows for shorter reaction times and better product purity.
2Productivity
If basic hydrolysis is used to reduce hydrolysis time, then the space-time-yield is improved, but additional steps are required to form pharmaceutically acceptable salts
Solution Approach 1:
The patent segments the overall process into two distinct stages: first, basic hydrolysis to produce the free base form (completing in ~1 hour), and second, separate salt formation with the desired pharmaceutically acceptable acid. This segmentation allows optimization of each stage independently, achieving fast hydrolysis while maintaining flexibility in salt selection.
Solution Approach 2:
Instead of directly forming the hydrochloride salt as in conventional acid hydrolysis, the patent inverts the approach by first forming the free base through basic hydrolysis, then converting to the desired salt form. This inversion provides both time efficiency and product flexibility.
3Productivity
If high temperatures are used for hydrolysis, then the reaction rate is increased, but unwanted by-products are formed and production costs increase
Solution Approach 1:
The patent changes the temperature parameter from high (conventional acid hydrolysis requires prolonged heating) to moderate temperatures. The basic hydrolysis proceeds efficiently at lower temperatures (e.g., 60-100°C) within one hour, reducing thermal stress and minimizing by-product formation while maintaining high reaction rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method results in high conversion rates and yields of 1-amino-3,5-dimethyladamantane with minimal by-products, enabling the production of Memantine hydrochloride in high purity and allowing for the formation of other desired salts directly, thus improving the space-time-yield and simplifying the process.
Implementation Method 1
The hydrolysis of 1-formamido-3,5-dimethyladamantane is conducted under basic conditions in a protic solvent
Data Source
AI summary
Method for producing 1-amino-3,5-dimethyladamantane or a salt thereof, comprising: (i) heating 1-formamido-3,5-dimethyladamantane with a base in a protic solvent.